Today: 7 February 2026
Subscribe

ServiceNow stock slips in year-end trade as thin volumes hit growth names — what to watch next

ServiceNow stock slips in year-end trade as thin volumes hit growth names — what to watch next

NEW YORK, December 31, 2025, 14:52 ET — Regular session ServiceNow shares edged lower on Wednesday as investors pared risk in thin year-end trading on Wall Street. The enterprise software maker’s stock was down about 0.3% at $153.81. The muted move came as major U.S. indexes drifted lower in the final session of 2025, with technology stocks slightly weaker on the day. “I do not expect that the last few days will have so much bearing on the performance of the next year,” Giuseppe Sette, co-founder and president of Reflexivity, said, pointing to profit-taking when liquidity is low. Reuters For
31 December 2025
····
Trump offshore wind freeze heads to court as judge seeks classified evidence in Dominion case

Trump offshore wind freeze heads to court as judge seeks classified evidence in Dominion case

NEW YORK, December 31, 2025, 14:45 ET A U.S. federal judge in Virginia has delayed Dominion Energy’s bid to quickly restart offshore construction on its Coastal Virginia Offshore Wind project, as the court seeks access to classified material the Trump administration says underpins its stop-work order. The next hearing is set for Jan. 16, after the judge directed the government to submit the classified information to the court by Jan. 9 and to say by Dec. 31 whether it would share that material with Dominion’s security-cleared lawyers. Maritime Executive The case has become an early legal test of President Donald
31 December 2025
··
India fires two Pralay missiles back-to-back in salvo test, signalling induction is near

India fires two Pralay missiles back-to-back in salvo test, signalling induction is near

NEW YORK, December 31, 2025, 14:29 ET India’s Defence Research and Development Organisation (DRDO) on Wednesday test-fired two indigenously developed Pralay missiles in quick succession off the coast of Odisha, in a user evaluation trial that officials said underscored the system’s readiness for service. The test matters because user evaluation trials are a late-stage proving process, typically involving the military “users” who will operate the system, and are usually among the final steps before formal induction. It also comes as India continues to strengthen its domestic weapons programme and expand conventional strike options, against the backdrop of long-running rivalry with
31 December 2025
··
Sidus Space stock jumps 33% as $16.2 million share sale settles

Sidus Space stock jumps 33% as $16.2 million share sale settles

NEW YORK, December 31, 2025, 2:48 PM ET — Regular session Shares of Sidus Space, Inc. (SIDU) jumped about 33% to $3.56 by 2:48 p.m. ET on Wednesday. The stock traded between $2.48 and $3.74, with about 112.7 million shares changing hands. The rally comes two sessions after Sidus said it closed a best-efforts public offering, raising about $16.2 million in gross proceeds by selling 10.8 million shares at $1.50 each. The company said it plans to use the funds for sales and marketing, operating costs, product development, manufacturing expansion, and working capital. Sidus Space, Inc. That matters for investors
31 December 2025
····
Pfizer stock today: PFE slips after report on 2026 U.S. drug price hikes

Pfizer stock today: PFE slips after report on 2026 U.S. drug price hikes

NEW YORK, December 31, 2025, 14:53 ET — Regular session Pfizer shares were down 0.1% at $24.96 in afternoon trade on Wednesday after a Reuters report said the drugmaker plans U.S. list-price hikes on about 80 medicines in 2026. Reuters The planned increases, set to start Jan. 1, land at a sensitive moment for drug pricing as the Trump administration presses the industry to lower costs. Annual list-price resets can also shape negotiations with insurers and the political risk premium investors apply to large drugmakers. Pfizer’s own outlook has put a spotlight on revenue durability. In its December guidance, Pfizer
31 December 2025
·····
CoreWeave stock drops as insider sale filing hits thin year-end trade — what’s next for CRWV

CoreWeave stock drops as insider sale filing hits thin year-end trade — what’s next for CRWV

NEW YORK, December 31, 2025, 14:40 ET — Regular session CoreWeave Inc shares were down 3.1% at $71.63 on Wednesday afternoon, after an insider sale disclosure drew attention in thin year-end trading. The stock hit a session low of $71.46. The timing matters because trading conditions are patchy heading into the New Year’s Day holiday, when lower liquidity can amplify moves in single names. For a recently listed company with a volatile tape, incremental supply can weigh on sentiment even without new fundamental news. Investors have also been sensitive to funding and dilution risk in capital-intensive AI infrastructure plays. CoreWeave
31 December 2025
····
Visa stock slips as escrow-linked share conversion update hits year-end trade

Visa stock slips as escrow-linked share conversion update hits year-end trade

NEW YORK, December 31, 2025, 14:37 ET — Regular session Visa Inc. shares edged lower on Wednesday, down $1.14, or 0.3%, at $352.48 in afternoon trading as investors digested a technical update tied to the payments giant’s U.S. litigation escrow account. The stock traded between $352.08 and $355.13. The filing matters because it highlights how Visa manages certain legacy legal exposures in the United States. Even mechanical changes that touch the share count can feed into earnings per share — a key yardstick for a company that returns significant capital to shareholders. The update also lands as traders position into
31 December 2025
····
Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing

Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing

NEW YORK, December 31, 2025, 14:41 ET — Regular session Axsome Therapeutics shares jumped 23% in afternoon trading on Wednesday after the company said U.S. regulators accepted its application and granted a faster review for AXS-05 to treat agitation in Alzheimer’s disease. GlobeNewswire The FDA’s acceptance puts a hard deadline on the next major catalyst for Axsome, with an April 30, 2026 decision target that brings clarity to the company’s regulatory timeline. The stock move also stood out against the broader biotech group, which was modestly higher. GlobeNewswire Axsome said the FDA granted “Priority Review,” meaning the agency’s goal is
31 December 2025
·····
UHS stock sinks today after CEO contract extension filing — here’s what moved the shares

UHS stock sinks today after CEO contract extension filing — here’s what moved the shares

NEW YORK, December 31, 2025, 13:23 ET — Regular session Universal Health Services, Inc. shares were down 2.75% at $218.87 in afternoon trading on Wednesday, extending losses as the hospital operator underperformed its peer group. The stock was down $6.19 from Tuesday’s close and touched $218.59 at the session low, with about 293,000 shares traded. The move matters now because governance and pay disclosures can become a catalyst in thin year-end trading, when investors reassess leadership incentives and stewardship. Hospital operators also enter 2026 facing close scrutiny on costs, staffing and reimbursement — areas where execution can swing margins quickly.
31 December 2025
····
Goldman Sachs stock slips on New Year’s Eve as Fed repo borrowing hits a record

Goldman Sachs stock slips on New Year’s Eve as Fed repo borrowing hits a record

NEW YORK, December 31, 2025, 14:39 ET — Regular session Goldman Sachs shares slipped on Wednesday as U.S. stocks drifted lower in holiday-thin trading on the final session of 2025. The stock was down 0.3% at $881.64 after swinging between $876.75 and $886.26 earlier in the day. The muted move still matters because year-end trading can exaggerate small flows. Portfolio rebalancing, tax positioning and balance-sheet constraints often make liquidity patchy, especially in big financial names. Traders were also watching short-term funding markets, where banks and dealers typically hunt for cash at quarter- and year-end. Signs of strain can spill into
31 December 2025
·····
Pitney Bowes NT 43 drops 3% today as Treasury yields rise — what’s next for PBI.PRB

Pitney Bowes NT 43 drops 3% today as Treasury yields rise — what’s next for PBI.PRB

NEW YORK, December 31, 2025, 14:16 ET — Regular session Pitney Bowes Inc.’s NT 43 — its exchange-listed notes due 2043 — fell 3.0% to $21.04 in afternoon trading on Wednesday, after opening at $21.65. The security traded between $21.00 and $21.72, with volume around 50,000 shares as U.S. 10-year yields moved higher. Investing.com The move matters because NT 43 trades like a stock but behaves like a bond: when market interest rates rise, fixed-rate income securities often fall as investors demand a higher yield. Liquidity can also thin late in the year, amplifying price swings in niche, income-focused listings.
31 December 2025
····
PayPal stock (PYPL) slips on last trading day of 2025 — what traders watch next

PayPal stock (PYPL) slips on last trading day of 2025 — what traders watch next

NEW YORK, December 31, 2025, 14:36 ET — Regular session PayPal Holdings (PYPL.O) shares were down 0.5% at $58.83 on Wednesday afternoon, tracking a modest dip in U.S. equities as investors positioned for year-end. The move matters because payments stocks tend to be sensitive to shifts in the economic outlook. Transaction volumes are closely tied to consumer spending, and valuations can swing with interest-rate expectations. Wednesday’s session also came with lighter liquidity ahead of the New Year’s Day holiday, making routine flows look bigger in price action. Reuters U.S. labor-market data provided the main macro headline of the day. Initial
31 December 2025
·····
1 … 1,051 1,052 1,053 1,054 1,055 … 2,708

Stock Market Today

Wesfarmers share price: what to watch on ASX next week as results loom

Wesfarmers share price: what to watch on ASX next week as results loom

7 February 2026
Wesfarmers shares closed down 1.33% at A$85.04 on Friday, following a sharp drop in the S&P/ASX 200, which fell 2% for its steepest one-day loss in 10 months. Investors are watching for Australia’s household spending data next week and Wesfarmers’ half-year results due Feb. 19.
Go toTop